Browse Articles

Discover research articles across all indexed journals

Enterobactin carries iron into Caenorhabditis elegans and mammalian intestinal cells by a mechanism independent of divalent metal transporter DMT1

Journal of Biological Chemistry Aileen K. Sewell, Mingxue Cui, Mengnan Zhu et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108158

Predictive factors for the efficacy of nal-IRI + 5FU/LV therapy in patients previously treated with conventional irinotecan.

Journal of Clinical Oncology Yasutsugu Asai, Satoshi Kobayashi, Kazumasa Shiraishi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.737

737 Background: There were some reports that nal-IRI + 5FU/LV (NAPOLI) therapy was effective for patients with unresectable pancreatic cancer who had a history of treatment containing conventional irinotecan (IRI) though the others did not. We aimed to investigate the factors that contribute to the effectiveness of NAPOLI therapy for patients who have already received IRI-containing treatment. Methods: We retrospectively enrolled the consecutive patients who had previously treated with IRI-containing treatment and started NAPOLI therapy at our hospital between June 2020 and December 2022. We compared the patient backgrounds of patients who achieved CR, PR, or SD according to RECISTv1.1 (effective group) and those who did not (ineffective group). Continuous variables were divided into two groups by the median of the entire population, and factors contributing to the effectiveness of NAPOLI therapy were determined by logistic regression analysis. Results: The subjective were 52 patients. The reason for discontinuation of IRI-containing treatment was refractory and intolerant in 45 and 7 patients, respectively. The median age was 65 years. Twenty-three patients (44%) had ECOG PS of 0, and 41 patients (79%) had metastatic disease. The median albumin, CRP, CEA and CA 19-9 was 3.8 g/dL, 0.3 mg/dL, 8.5 ng/mL and 2082 U/mL, respectively. Twenty-one patients (40%) showed SD and they were allocated in the effective group whereas 31 patients were in the ineffective group. Of the 21 patients in the Effective Group, 16 patients(76%) were refractory, while of the 31 patients in the Ineffective Group, 29 patients (94%) were refractory. The factors contributing to disease control were PS of 0 (odds ratio, 5.79; 95% confidence interval, 1.34–25.0), CA 19-9 <1000 U/mL (odds ratio, 5.53; 95% confidence interval, 1.26–24.3), and Alb >3.8 g/dL (odds ratio, 5.19; 95% confidence interval, 1.14–23.7). Age, sex, disease stage, serum level of CRP, and CEA did not affect the effectiveness of NAPOLI therapy. Conclusions: Even in patients who have already received IRI treatment, the NAPOLI regimen is expected to be effective in patients with PS of 0, Alb >3.8 g/dL, and CA 19-9 <1000 U/mL.

The prevalence of Lynch syndrome and associated clinicopathologic features in patients with mismatch repair deficient gastric cancer.

Journal of Clinical Oncology Sun Mi Lee Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.380

380 Background: Approximately 2-4% of patients with primary colorectal cancer are estimated to be associated with Lynch syndrome. However, the prevalence of Lynch syndrome and associated clinicopathologic features in patients with mismatch repair-deficient (dMMR) gastric cancer (GC) is not well understood. In this study, we investigated the frequency of dMMR GCs in unselected GCs and the prevalence of Lynch syndrome, as well as associated clinicopathologic features and molecular alterations in dMMR GCs. Methods: A total of 847 cases of unselected GCs from 2010 to 2012 were collected at Jeju National University Hospital. Immunohistochemistry for mismatch repair proteins (MMR), including MLH1, MSH2, MSH6, and PMS2, and MSI analysis were performed on representative tumor sections of surgically resected specimens. Follow-up genetic counseling and genetic and/or epigenetic alterations of the MMR genes were also investigated. Results: Loss of one or more MMR proteins and microsatellite instability-high were observed in 72 patients; 67 patients showed loss of MLH1/PMS2, 2 patients showed loss of PMS2 alone, and 3 patients with MSH2/MSH6. Genetic counseling demonstrated that ten patients had a family history of LS-associated cancers and nine patients had a history of metasynchronous cancers. Of the 72 patients, 65 revealed hypermethylation of the promoter region of MLH1. The subsequent genetic germline tests demonstrated 2 patients with MLH1 mutation, 3 with MSH2 mutation, and 2 with PMS2 mutation. Conclusions: dMMR tumors were identified in 72 (8.5%) of 847 unselected primary GCs. This study estimated that 0.8% of patients with unselected GC and 9.7% of patients with dMMR GC fulfilled the revised Bethesda criteria and are associated with Lynch syndrome. The detection of dMMR GCs and necessary genetic counseling/tests based on revised Bethesda criteria would help find Lynch syndrome in patients with GC. Clinical and immunophenotypical features of patients with dMMR GC. Age ≤ 50 years 5 (6.9) > 50 years 67 (93.1) Other malignancy history except GAC No 63 (87.5) Yes 9 (12.5) History of metachronous cancers Esophageal cancer 1 (1.4) Maxillary sinus cancer 1 (1.4) Papillary thyroid cancer 1 (1.4) Colorectal cancer 1 (1.4) Pancreatic cancer 1 (1.4) Breast cancer 1 (1.4) Breast cancer and malignant GIST 1 (1.4) Multiple HCCs 2 (2.8) History of Family with LS related cancers No 62 (86.1) Yes 10 (13.9) Fulfillment of the rBG No 63 (87.5) Yes 9 (12.5) MMR proteins Loss of MLH1 and PMS2 67 (93.1) Loss of PMS2 2 (2.8) Loss of MSH2 and MSH6 3 (4.2) Germline mutation test MLH1 mutations 2 (2.8) MSH2 mutations 3 (4.2) PMS2 mutations 2 (2.8)

Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.

Journal of Clinical Oncology Nadia Hitchen, Hui-Li Wong, Rachel Wong et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.70

70 Background: BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less responsiveness to chemotherapy. The BEACON CRC study demonstrated that encorafenib plus cetuximab (EC) significantly improved overall survival (OS) compared to FOLFIRI plus cetuximab in BRAF-mutant mCRC as 2 nd or 3 rd line therapy. This combination was reimbursed in Australia from January 2022. Methods: We analysed data from the Australian TRACC mCRC clinical registry, encompassing patients (pts) with BRAF-mutant mCRC diagnosed in Australia from 2009 to 2024 at 31 hospitals. We assessed baseline demographics, uptake of EC following reimbursement and efficacy analysis of progression-free survival (PFS) and OS for pts that received EC and those who did not. Pts receiving EC on a clinical trial were excluded. Results: Among 2,800 pts with known BRAF mutation status, 365 (13%) were BRAF mutated. The BRAF mutant cohort had a median age of 63 years, with a significantly higher mutation rate in the 20-39 age group than other age groups (age 20-39, 25.5%; age 40-59, 10%; age 60+, 13.2%; P<0.001); 54.5% were female, 58% right-sided tumours, 64% with synchronous metastatic disease and 21.7% deficient mismatch repair (dMMR). Overall, 314 (86%) pts with BRAF mutant tumours and 2,079 (85%) BRAF wild-type (WT) tumours received 1 st line treatment, and 156 (43%) BRAF mutant and 1,144 (47%) BRAF WT pts received 2 nd line therapy. The median OS from diagnosis was 17.3 months for BRAF mutant pts versus 34.7 months for BRAF WT pts (p < 0.0001). All dMMR BRAF mutant pts received 1 st line pembrolizumab since its reimbursement in August 2021. Among 41 BRAF mutant pts progressing on 1 st line therapy since January 2022,(32 pMMR, 9 dMMR), 33 (80%) were subsequently treated with EC, and 4 (10%) did not receive further treatment. OS from the start of 2 nd line therapy was 9.6 months (95% CI: 7.2-12.5) for pts who received EC and 7.1 months (95% CI: 6.4-8.6) for those who received other systemic treatment. Median PFS for pts receiving EC was 4.6 months (95% CI: 3.4-5.8) and 3.3 months (95% CI: 2.5-5.3) for other 2 nd line treatments. Conclusions: mCRC pts younger than 40 have a high rate of BRAF mutation, where 1 in 4 tumours harbour the mutation. BRAF mutant mCRC has a poorer outcome than BRAF WT despite a similar proportion receiving 1 st and 2 nd line treatment. The majority of eligible BRAF mutant mCRC pts received EC following reimbursement in Australia, with PFS and OS outcomes consistent with the BEACON CRC trial.

IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)—The IKF-IMMULAB trial.

Journal of Clinical Oncology Arndt Vogel, Oliver Waidmann, Thomas Christian Wirth et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.582

582 Background: Ablation of neoplastic tissue through radiofrequency ablation (RFA), microwave ablation (MWA), or brachytherapy is a potentially curative option for patients with early stage hepatocellular carcinoma (HCC); however, recurrence rates are high. While updated results from IMbrave050 do not support the use of adjuvant therapy following resection or local therapy, the potential of peri-interventional systemic treatment as a potentially more effective approach to increase recurrence free and long-term survival remains to be determined. We propose that peri-interventional treatment with pembrolizumab may improve outcomes following local ablative therapies. Methods: This single arm phase II trial investigates peri-interventional treatment with pembrolizumab combined with RFA/MWA or brachytherapy, or - as recommended for tumors ≥ 3 cm - by combination with TACE in early stage HCC with maintained liver function. 200 mg of pembrolizumab (q3w) was administered intravenously for 2 cycles followed by radiologic imaging and local therapy. Pembrolizumab was continued for up to 12 months. Primary endpoint was radiological response rate according to RECIST 1.1 prior to local therapy. Results: 30 pts (ECOG 0 or 1) were enrolled in 9 centers in Germany with a median age of 70 years (73.3% males, median tumor size 25 mm with minimum of 10 mm and maximum of 72 mm, 60% solitary lesions). All pts received at least 1 dose of study treatment and the median number of cycles was 13. ORR was 13.3% with 6.7% CR and 6.7% PR after two cycles. After a median follow-up of 34.5 months, median time to recurrence (TTR) was 16.43 months, with 8 pts remaining free of recurrence. mOS was not reached, with a 2y OS rate of 76% and a 3y OS rate of 66%. No new safety signs were observed. Subsequent local ablation was performed in 13 pts, and 10 pts started on systemic therapies (5 TKI, 3 ICI and 2 pts received TKI and ICI). Conclusions: In the IKF-IMMULAB trial the expected objective response rate of 30%, according to RECIST1.1., prior to local therapy was not reached. However, with recent evidence that radiologic response underestimates pathological response in ICI-treated HCC patients and supported by a 2y OS rate of 76% and a 3y OS rate of 66%, there is evidence for the efficacy of peri-interventional treatment with pembrolizumab without new safety signals. Clinical trial information: NCT03753659 .

HIV/AIDS and HBV co-infection with optimal control strategies and cost-effectiveness analyses using integer order model

Scientific Reports Shewafera Wondimagegnhu Teklu, Abushet Hayalu Workie Feb 01, 2025 DOI: 10.1038/s41598-024-83442-z

Calmodulin enhances mTORC1 signaling by preventing TSC2-Rheb binding

Journal of Biological Chemistry Yuna Amemiya, Yuichiro Ioi, Makoto Araki et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108122

Exploration of novel biomarkers and novel therapies for immune checkpoint inhibitors (ICIs) in genetic variants of esophageal squamous cell carcinoma (ESCC): A study of 1,059 Japanese cases.

Journal of Clinical Oncology Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.495

495 Background: In Japan, cancer genome profiling (CGP) tests will be covered by insurance in 2019, and more than 1,000 ESCC cases have been accumulated in the national database. ICIs are currently the key drugs for esophageal cancer, and MSI and TMB status can work as biomarkers for ICIs in solid tumors. Therefore, to improve the prognosis of esophageal squamous cell carcinoma (ESCC), we aim to search for gene variants that may predict the efficacy of ICIs and explore the possibility of new treatment from genetic data accumulated in the Japanese nation-wide C-CAT database. Methods: We retrospectively analyzed 1,059 ESCC cases from C-CAT data accumulated from June 2019 to February 2024. We used the registered clinical and genetic information to examine gene variants and carcinogenic pathways that could serve as biomarkers for ICIs. Results: Of the 1059, 152 (14.4%) had TMB-H and 3 (0.3%) had MSI-H, with a median TMB of 5.0 Muts/Mb (range: 0-268). XPO1 and TP53 were found to be positively and negatively correlated as genes affecting TTF in nivolumab monotherapy (FDR P value < 0.01). TMB has the potential to be a biomarker for ICI, but TMB was significantly higher in the group with variants in the ARID family ( ARID2 , ARID1A plus ARID5B ) (median TMB 5.0 vs 8.0 Muts/Mb, P<0.001). In addition, 709 patients (66.9%) had any variants in three pathways (TP53, RTK and cell cycle), which are thought to be involved in the carcinogenesis of ESCC. PIK/Akt/mTOR and epigenetic modulation pathways were also found to be abnormal in many cases, and abnormalities in the epigenetic modification pathway were found to contribute significantly to TMB-H (FDR P value<0.01, Logarithmic value=19.2). Conclusions: This is the first case-specific report on the relationship between mutations in the ARID family and TMB in ESCC and the signalling pathways leading to carcinogenesis. In the present study, the association between the ARID family and TMB, and between abnormalities in the epigenetic modification pathway and TMB, which has been previously reported in other cancer types but not in esophageal cancer, suggests that multiple pathological mutations including these may be new biomarkers for ICI in 1059 Japanese patients. Furthermore, multiple pathways are often involved in ESCC carcinogenesis at the same time, and a separate, combined approach that takes these into account may be necessary in the development of new drugs.

Real-world genomic testing performance in colorectal cancer (CRC): The MultiTEAM Systems Framework Precision Oncology Reflex Testing (TEAMSPORT).

Journal of Clinical Oncology Haoran Li, Carolyn Frances Caine, Barsha Halder et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.108

108 Background: Genomic testing plays a pivotal role in personalizing treatment for CRC patients. Despite recommendations from NCCN, adoption remains uneven. Research indicates that only 64.7% of patients with metastatic CRC (mCRC) underwent molecular testing nationwide. TEAMSPORT seeks to address this gap by evaluating the feasibility of reflex testing and examining how pathology and oncology teams integrate genomic testing into routine practice. Methods: This quasi-experimental study tracks testing over time. Eligible patients were 18 years or older, with a histological diagnosis of adenocarcinoma, who received treatment at the University of Kansas Health System (TUKHS). Exclusion criteria included patients discharged to hospice after diagnosis, those whose last contact with TUKHS occurred within 30 days of diagnosis, and patients who passed away within 30 days of diagnosis. Testing rates were calculated as the number of tests performed divided by the number of testing opportunities, where "testing opportunities" refer to NCCN-recommended tests based on cancer stage. An intervention to increase adherence to NCCN-recommended testing began in December 2022. Results: From January 2022 to December 2023, 564 colorectal cancer (CRC) cases were eligible for genomic testing, resulting in 1,525 testing opportunities. In localized CRC, testing rates steadily improved, from 92% in January-June 2022 to 98% by July-December 2023 for patients diagnosed outside of TUKHS. At TUKHS, the rates remained high, reaching 100% in the first two periods and staying over 90% in subsequent periods. Patients with mCRC saw similar trends, particularly in the control arm where rates went from 61% to 71%. Specific molecular NCCN-recommended tests were assessed. At TUKHS, testing rates were high for microsatellite instability (MSI - 98%) which is caused by deficiency of the DNA mismatch repair (dMMR) system. Lower testing rates were observed for other markers like KRAS (70%), BRAF (67%) and HER2 (48%). Testing rates were assessed based on primary insurance. At TUKHS, the testing rates for Medicaid patients reached 94%, private insurance patients at 78%, and Tricare/VA at 100%. Outside of TUKHS, Medicaid patients had lower testing rates at 21%, private insurance patients at 74%, and CMS patients at 66%. Time to test by processing lab will be presented at the meeting. Conclusions: Despite the high testing rates for MSI/dMMR, the overall genomic testing in CRC remains imperfect, with lower rates for BRAF and HER2 . This discrepancy may be related to the fact that targeted therapies for BRAF and HER2 are not yet part of first-line treatment for CRC. Causes for the discrepancy in testing rates by primary insurance have yet to be determined. Future research should address these gaps to enhance precision oncology in CRC management.

A safety trial of antibiotic fecal microbiota transplantation for esophageal and gastric cancer patients treated with immune checkpoint inhibitors (Biorich2 trial).

Journal of Clinical Oncology Yuri Yoshinami, Hirokazu Shoji, Natsuko Tsuda Okita et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps510

TPS510 Background: The development of immune checkpoint inhibitors (ICIs) has improved the prognosis of unresectable advanced or recurrent esophageal and gastric cancer. However, the prognosis remains poor. The human intestinal microbiota plays various roles in digestion, immunomodulation, and metabolism and is known to influence tumor suppression. Previous studies reported that intestinal microbiota can impact immune responses and the effectiveness of ICIs. Therefore, this study investigates the safety and efficacy of antibiotic fecal microbiota transplantation (A-FMT) in patients with unresectable advanced or recurrent esophageal or gastric cancer. Methods: Eligible patients are diagnosed with unresectable advanced or recurrent esophageal squamous cell carcinoma or gastric adenocarcinoma. The primary endpoint is to examine the dose-limiting toxicity (DLT) of A-FMT. Secondary endpoints include response rate, disease control rate, progression-free survival, overall survival, and biomarkers of efficacy and adverse events. This trial consists of two parts: safety confirmation, which assesses DLT incidence, and an expansion part, which examines efficacy and safety. The safety confirmation part will enroll 3-6 patients in cohort 1 (combination therapy with ICIs and chemotherapy) and cohort 2 (combination of anti-PD-1 and anti-CTLA4 antibodies). The expansion part will enroll untreated patients: 10 for esophageal cancer (ICIs + chemotherapy), 10 for anti-PD-1 + anti-CTLA4 antibodies, and 11 for gastric cancer (ICIs + chemotherapy). After enrollment, patients receive antibacterial agents for 1 week before FMT. Patients then undergo total colonoscopy after bowel cleaning with polyethylene glycol plus ascorbic acid. A 200 mL fecal suspension from a healthy donor is transferred to the patient's cecum, and ICIs with/without chemotherapy are initiated thereafter. Biomarker analysis explores diagnostic or surrogate biomarkers, aiming to identify molecular targets, cell populations, microbial species, and functions involved in efficacy by analyzing the effects of A-FMT and ICIs on the tumor microenvironment and intestinal microbiota using methods such as proteome analysis. This trial is registered in the Japan Registry of Clinical Trials as jRCTs031240170 and was initiated in August 2024, with enrollment ongoing. Clinical trial information: jRCTs031240170.

Analyzing disease control through testing game approach embedded with treatment and vaccination strategies

Scientific Reports Abhi Chakraborty, Md. Fahimur Rahman Shuvo, Faiza Farheen Haque et al. Feb 01, 2025 DOI: 10.1038/s41598-024-84746-w

MAP3K4 signaling regulates HDAC6 and TRAF4 coexpression and stabilization in trophoblast stem cells

Journal of Biological Chemistry Hannah A. Nelson, Nathan A. Mullins, Amy N. Abell Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108116

The impact of protein-energy malnutrition on outcomes in patients with cholangiocarcinoma admitted with sepsis: Insights from a national database.

Journal of Clinical Oncology Adamsegd Isac Gebremedhen, Jennifer Wiese, Ibrahim Shanti et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.535

535 Background: Patients with cholangiocarcinoma (CCA) are prone to infection and related complications. Protein-energy malnutrition (PEM) is common among these patients, arising from either the malignancy or its treatments. PEM is linked to worse medical and surgical outcomes and longer hospital stays across various cancers. The impact of PEM on CCA patients with sepsis, however, remains underexplored. This study aims to fill this gap by assessing how PEM affects in-hospital outcomes in CCA patients admitted with sepsis. Methods: We queried the Healthcare Cost and Utilization Project National Inpatient Sample and identified adult patients with CCA admitted with the principal diagnosis of sepsis from 2018 to 2021, using the ICD-10 code. We categorized the cohort based on the presence or absence of PEM and applied complex sampling weights for national representativeness. We compared socio-demographic characteristics and comorbidities between CCA patients with sepsis who have PEM and those who do not. The primary outcome studied was all-cause in-hospital mortality. Secondary outcomes examined were acute kidney injury (AKI), renal replacement therapy (RRT), respiratory failure (RF), invasive ventilation (IV), septic shock, vasopressor requirement (VP), mean length of hospital stay (LOS), and mean total hospitalization charges (THC). Multivariate regression models assessed outcome disparities between groups, adjusting for patient characteristics and comorbidities, with statistical significance set at p < 0.05. Results: We identified a total of 22,680 adults with CCA who were admitted with the principal diagnosis of sepsis from 2018 to 2021. Among these, 7,245 patients (31.9%) had a concurrent diagnosis of PEM. The PEM group had a higher proportion of female (47.3% vs 44.1%, p=0.04) and non-white (41.7% vs 37.2%, p<0.001) patients and patients with Charlson Comorbidity Index > 3 (86.5% vs 83.3%, p<0.001). Patients with PEM had higher odds of all-cause in-hospital mortality with an adjusted odds ratio (aOR) of 1.26 (95% confidence interval (CI) 1.05-1.51). They also had higher odds of AKI with an aOR of 1.32 (95% CI 1.16-1.50), RF with an aOR of 1.30 (95% CI 1.09-1.51), and septic shock with an aOR of 1.22 (95% CI 1.06-1.40). Patients with PEM also had a higher LOS (9.0 vs 6.3 days) with an adjusted incidence rate ratio (aIRR) of 1.41 (95% CI 1.33-1.49) and THC ($115,971 vs $83,176) with aIRR of 1.35 (95% CI 1.25-1.45). Conclusions: Our study revealed that CCA patients with PEM admitted with sepsis had significantly higher odds of in-hospital mortality, AKI, RF, and septic shock compared to those without PEM. They also experienced longer hospital stays and higher hospitalization charges. These findings highlight the urgent need to address PEM in CCA patients and tailor inpatient management to reduce complications in this high-risk group.

Prognostic analysis of pathological complete response after neoadjuvant therapy for locally advanced gastric cancer: A national, multicenter, retrospective study.

Journal of Clinical Oncology Jie Chen, Yingxue Liu, Chao Lin et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.346

346 Background: Several research findings indicate that some patients with locally advanced gastric cancer (LAGC) who undergo neoadjuvant therapy followed by curative surgery can achieve pathological complete response (pCR). Whether pCR is equivalent to cure, serves as a good prognostic indicator for long-term survival, and whether patients achieving pCR require subsequent adjuvant therapy are still unknown. Therefore, we conducted a nationwide multicenter retrospective study to investigate the long-term efficacy of patients with LAGC who achieved pCR after neoadjuvant therapy. Methods: Clinical and pathological data were collected from 351 patients with locally advanced gastric cancer who achieved pCR after neoadjuvant therapy between January 2018 and October 2023 at 14 medical centers in China. These patients were matched 1:1 with non-pCR patients based on age, gender, clinical T stage, and N stage. This study evaluated general clinical data, neoadjuvant treatment regimens, cycles, surgical outcomes, and follow-up information including postoperative adjuvant therapy, recurrence, metastasis, and survival status up to November 2023. Results: Negative Serum tumor markers, non-signet ring cell carcinoma and neoadjuvant treatment regimens were closely associated with pCR. Patients achieving pCR were more likely to reach ypN0 status after neoadjuvant therapy compared to non-pCR patients. Survival analysis showed significantly higher overall survival (OS) and disease-free survival (DFS) in pCR patients compared to matched non-pCR patients. Moreover, OS and DFS were significantly higher in ypN0 patients within the pCR group compared to non-pCR patients. However, there was no significant difference in OS and DFS between ypN+ patients in the pCR group and non-pCR patients. Additionally, postoperative adjuvant chemotherapy did not significantly impact OS and DFS in the pCR group. Conclusions: pCR is an independent prognostic factor for OS and DFS. However, survival benefits from pCR are limited to patients achieving ypT0N0 status, while ypT0N+ patients do not benefit from pCR. Furthermore, adjuvant chemotherapy may not improve the prognosis of patients achieving pCR after neoadjuvant therapy.

Nirogacestat in patients with desmoid tumors and mutations of adenomatous polyposis coli ( <i>APC</i> ): Findings from the DeFi trial.

Journal of Clinical Oncology Noah Federman, Bernd Kasper, Peter Reichardt et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.134

134 Background: Nirogacestat (niro) is an oral, targeted gamma secretase inhibitor FDA-approved for adults with progressing desmoid tumors (DT) who require systemic treatment. In the phase 3 DeFi trial (NCT03785964), niro demonstrated significant improvement vs placebo (pbo) in progression-free survival (PFS; HR 0.29 [95% CI: 0.15–0.55], P &lt;.001) and objective response rate (ORR; 41% vs 8%, P &lt;.001). Most DT are sporadic tumors characterized by somatic mutations in the CTNNB1 gene. About 10%–20% of DT are associated with APC mutations, the majority being germline that may cause familial adenomatous polyposis (FAP), an inheritable trait linked to an increased risk of colorectal cancer and may also confer more aggressive DT behavior. Methods: In DeFi, adult patients (pts) were randomized to oral niro (150 mg) or pbo twice daily. In pts with evaluable blood and tumor samples, descriptive post hoc analyses assessed effects of niro in pts with germline and/or somatic APC mutations, including pts with co-occurring somatic mutations of APC and CTNNB1 . Results: Of the 142 pts in DeFi, 29 pts had APC mutations (niro=13, pbo=16; 22 somatic, 21 germline, and 14 somatic and germline), including 3 pts (niro=2, pbo=1) with co-occurring somatic mutations of APC and CTNNB1 . Of these 29 pts, 19 (66%) were female, 16 (55%) were aged ≤30 y, 22 (76%) had a family history of FAP, and 22 (76%) were refractory to prior therapy (median of 3 prior lines of therapy). PFS was improved with niro vs pbo (HR 0.21 [95% CI: 0.05–1.00], P =.016). Confirmed ORR was 38% (5/13) for niro vs 13% (2/16) for pbo; median time to response with niro was 8.31 months. All 3 pts with co-occurring somatic mutations of APC and CTNNB1 were female, aged 18–56 y, had DT in the upper extremity or abdominal wall, and had no family history of FAP. The 2 pts on niro had received prior systemic therapy and/or surgery and the 1 pt on pbo had no prior therapy. Of the 2 pts on niro, both achieved a partial response (median time to response: 9.9 months). The 1 pt randomized to pbo experienced disease progression in 2.6 months. In pts with APC mutations, diarrhea was the most frequently reported adverse event. In niro-treated pts, increased rates of skin events (maculopapular rash, 62%; dermatitis acneiform, 38%) and stomatitis (46%) were reported in pts with APC mutations compared with those in the overall DeFi population (32%, 22%, and 29%, respectively). Conclusions: Improvement in PFS and ORR was observed with niro vs pbo in pts with DT harboring APC mutations. Efficacy and safety of niro in pts with APC mutations were generally consistent with findings for the overall DeFi population. Although analyses were limited due to small sample size, these results suggest that niro can provide clinically meaningful benefit to pts with progressing DT and APC mutations, including those with co-occurring somatic mutations of APC and CTNNB1 . Clinical trial information: NCT03785964 .

A preliminary simulator study on exploring responses of drivers to driving system reminders on four stimuli in vehicles

Scientific Reports Zhao Zou, Fady Alnajjar, Michael Lwin et al. Feb 01, 2025 DOI: 10.1038/s41598-025-87571-x

A PDZ-kinase allosteric relay mediates Par complex regulator exchange

Journal of Biological Chemistry Elizabeth Vargas, Rhiannon R. Penkert, Kenneth E. Prehoda Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108097

Treatment patterns in patients with advanced gastrointestinal stromal tumor in Japan: An administrative claims database study.

Journal of Clinical Oncology Yoshito Komatsu, Yoichi Naito, Yuko Hirano et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.811

811 Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Tyrosine kinase inhibitors, including imatinib, sunitinib, and regorafenib, and the HSP90 inhibitor, pimitespib have been approved for advanced GIST in Japan, but few studies have examined the nationwide trend in treatment patterns. This study aimed to evaluate the real-world treatment patterns for advanced GIST in Japan. Methods: This retrospective cohort study used the Japanese hospital-based administrative claims database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan). Patients diagnosed with advanced GIST according to ICD-10 codes who received any approved standard drug in Japan, such as imatinib, sunitinib, regorafenib, or pimitespib (Approved in June 2022) between July 2013 and March 2023 were included. The primary endpoint was the proportion of patients with GIST who were treated with each approved standard drug. Secondary endpoints included treatment patterns, time to treatment failure (TTF), overall survival, adverse events, and the proportion of patients who underwent surgical intervention for GIST while taking standard drugs. Results: This study included 2702 patients with advanced GIST. The median age was 70.0 years, 17% of the patients were ≥80 years, and 59% were male. The most common primary tumor sites were the stomach (37%), small intestine (25%) and large intestine (12%). The proportions of patients with GIST treated with imatinib, sunitinib, regorafenib, and pimitespib were 94% (2536 patients), 26% (702 patients), 14% (376 patients) and 1% (37 patients), respectively. The most common first-line regimen was imatinib (2485/2702 patients; 92%), second-line regimen was sunitinib (560/672 patients; 83%), third-line regimen was regorafenib (200/317 patients; 63%), and fourth-line regimen was imatinib (55/119 patients; 46%). The median TTF was 30.4 months (95% CI 27.4–32.9) with imatinib, 6.4 months (95% CI 5.6–7.7) with sunitinib, 5.2 months (95% CI 4.4–6.2) with regorafenib and 2.5 months (95% CI 1.7–3.1) with pimitespib. The proportions of patients who underwent surgical intervention for GIST was 15% (403/2702 patients), and curative surgery was 10% (273/2702 patients). Conclusions: This is the first real-world study to provide insights into the patient characteristics and current treatment patterns for advanced GIST in Japan. The treatment patterns are consistent with the Japanese Clinical Practice Guidelines.

A phase I, single-center, open label, dose de-escalation and expansion study of Ivosidenib + mFOLFIRINOX in patients with resectable pancreatic adenocarcinoma.

Journal of Clinical Oncology Ho Jun Lee, Lauren E. Henke, Jennifer Anne Dorth et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps794

TPS794 Background: Pancreatic ductal adenocarcinoma (PDA) carries a dismal prognosis, with a 34% 5-year survival rate for patients with localized disease. Guidelines recommend consideration of neoadjuvant approaches in localized PDA with the goals of controlling microscopic metastatic disease and increasing rates of microscopically margin-negative resections. One of the hallmark characteristics of PDA is a micronutrient poor, highly stromal microenvironment. Surviving in this environment requires enhanced mitochondrial function, which utilizes isocitrate dehydrogenase 1 (IDH1). In pre-clinical studies, ivosidenib, an FDA approved medication for IDH1 mutant AML, induced high levels of reactive oxygen species in PDA cells with wild-type IDH1, and caused tumor regressions and extended survival in implanted KPC mouse models. Here, we investigate the addition of ivosidenib to standard of care neoadjuvant mFOLFIRINOX in patients with resectable PDA to determine safety, pharmacodynamics, and early efficacy signals. Methods: This is a phase I, single-center, open label, dose de-escalation and expansion study in patients with resectable PDA. Eligible patients must have histologically confirmed and resectable right-sided PDA based on CT or MRI imaging. Patients receive approximately 10 weeks of neoadjuvant treatment composed of 2 weeks of ivosidenib monotherapy, followed by 6 weeks (3 cycles) of mFOLFIRINOX with ivosidenib, followed by up to 4 weeks of ivosidenib monotherapy until the day of surgery. Ivosidenib is administered once daily at 500mg; it is to be de-escalated to 250mg based on Bayesian Optimal Interval Design with Informative Prior and a target dose limiting toxicity (DLT) rate of 30%. The primary endpoint is to determine the safety and tolerability of ivosidenib in combination with mFOLFIRINOX. Secondary endpoints include RECIST version 1.1 response rates, major pathologic response rates, and biochemical (CA19-9, CEA) response rates. Correlative studies will be performed on surgical samples to evaluate metabolomic profiles. At the time of submission, 10 out of 16 planned patients have been enrolled. There have been no DLT at 500mg of ivosidenib. Clinical trial information: NCT05209074 .

The role of sequential PET/CT imaging to predict complete response after definitive chemoradiotherapy for locally advanced squamous cell carcinoma of the anal canal.

Journal of Clinical Oncology Marianna Valzano, Michele Aquilano, Mauro Loi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.12

12 Background: The standard treatment for locally advanced squamous cell carcinoma of the anal canal (SCCAC) is definitive radiotherapy (RT) with concurrent chemotherapy (CRT), with excellent outcomes. Nevertheless, rates of locoregional failure of 10% to 30% have been reported. Due to the narrow therapeutic window between time-dependent response to RT and prompt salvage surgery, the definition of a surveillance strategy after radical CRT is challenging. In particular the contribution of 18-FDG PET/CT is not clearly established. The purpose of this study was to evaluate the effectiveness of follow-up MR and 18-FDG PET/CT to predict response to CRT in patients with SCCAC. Methods: We analyzed a cohort of consecutive patients who received definitive RT/CRT from January 2019 to February 2024. After completion of therapy, radiologic (rCR) and metabolic complete response (mCR) was assessed with pelvic MR (RECIST v.1.0) and 18-FDG PET/CT at 3 ad 6 months respectively. Local Control (LC) was defined as time from the end of CRT to local failure or last follow-up. Univariate analysis (UVA) was performed to identify variables associated with outcome using the log rank test. Sensitivity and Specificity analysis was performed to assess the correlation between rCR/mCR and LC. Results: A total of 67 patients (median age 67 years, range 44-83) were included. All patients completed RT, and 52 received concurrent CRT. Baseline and surveillance MR and 18-FDG PET/CT were available for 49 patients. After a median follow-up of 28 months, 12 patients experienced disease progression (PD) (10 local; 2 distant), resulting to salvage surgery in 10 cases after biopsy. At 3 years, LC rate was 78%. At UVA, only mCR was correlated with LC (3-year LC 90% versus 59%, p=0,0137; HR 0,01660, IC 95% 0,03-0,84). For prediction of LC, accuracy of mCR at 6 months was 83.7% versus 62.5% for rCR. Specificity/Sensitivity analysis is summarized in the table. Conclusions: 18FDG PET/CT at 6 months may identify patients with a higher likelihood of developing complete tumor regression following CRT. Further data is needed to confirm the appropriate surveillance strategy for patient undergoing CRT in clinical practice. Specificity and sensitivity analysis. Sensitivity Specificity Positive Predictive Value Negative Predictive Value mCR 83.3% 84.0% 92.6% 68.7% rCR 25.0% 70.0% 14.0% 82%